Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment Strategy
Journal of Clinical Medicine · 23.04.2025 · 14 (9) · 2898
DOI: 10.3390/jcm14092898 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.04.2025. Verfasst von Janice Pakkianathan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anaplastic thyroid carcinoma (ATC) is the rarest and most aggressive form of thyroid cancer, marked by a poor prognosis and resistance to conventional treatments. Like many malignancies, ATC has a complex genetic landscape, with numerous mutations driving tumor initiation, progression, and therapeutic resistance. However, recent advances in molecular research have expanded our understanding of these genetic alterations, paving the way for new targeted treatment strategies. Currently, therapies targeting specific genetic mutations, such as BRAF and MEK, show promise, but their effectiveness is limited to patients harboring these mutations. To explore broader therapeutic possibilities, we conducted a comprehensive literature review using the PubMed database and Google to identify studies on key genetic mutations in ATC. By leveraging these molecular insights, we aim to highlight potential therapeutic avenues that could enhance treatment options and improve patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
- Center for Health Disparities & Molecular Medicine, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
- Department of Otolaryngology, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
ORCID-Profile: Janice Pakkianathan, Salma Khan
Zitieren
APA
Pakkianathan, J., Yamauchi, C. R., Barseghyan, L., Cruz, J., Simental, A. A., & Khan, S. (2025). Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment Strategy. Journal of Clinical Medicine, 14(9), 2898. https://doi.org/10.3390/jcm14092898
Vancouver
Pakkianathan J, Yamauchi CR, Barseghyan L, Cruz J, Simental AA, Khan S. Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment Strategy. Journal of Clinical Medicine. 2025;14(9):2898. doi:10.3390/jcm14092898
BibTeX
@article{Pakkianathan2025,
author = {Pakkianathan, Janice and Yamauchi, Celina R and Barseghyan, Luiza and Cruz, Joseph and Simental, Alfred A and Khan, Salma},
title = {Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment Strategy},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {9},
pages = {2898},
doi = {10.3390/jcm14092898}
}
EUVIMED